A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
Primary Purpose
Diabetes Mellitus, Type II
Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
CKD-395 0.25/500mg
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type II
Eligibility Criteria
Inclusion Criteria:
- A healthy male whose age is over 19 years old when visiting for initial screening test
Body mass index (BMI) between 17.5 ~ 30.5 kg/m^2 and the body weight must be over 55kg
- Body mass index (BMI) = weight (kg) / height (m)^2
- A male with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area
- Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc.
- The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.
- The participants must have an ability and willingness to participate throughout the entire trials
Exclusion Criteria:
- A person who had a history or symptoms of clinically aware of blood, kidney, internal secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nervous, or allergic (except subclinical seasonal allergies that is not treated at injection) disease.
- Who had a history of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy)
Who had following results after examination
a. ALT or AST > twice higher than normal value
- Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (12%) (125 mL) = 12 g)
- Who participated other clinical test or took testing bioequivalence drugs in 3 months before the first clinical drug trial
- Whose blood pressure > 140 mmHg (systolic blood pressure) or > 90 mmHg (diastolic pressure)
- Who had a medical history of alcohol and drug abuses.
- Who had taken a drug that has a control of metabolic rate (activation or inhibition) in 30 days before the first taking of clinical testing drug
- Who smokes more than 20 cigarettes per day
- Who took prescribed drugs or over-the-counter drugs in 10 days before taking of very first clinical testing drug
- Who participated in whole blood donation in 2 months before the first taking of clinical testing drugs or platelet donations in 1 month before the first taking to clinical testing drugs.
- Who has a potent to increase a danger by participating in the clinical trials or who can interrupt interpreting test results by having serious or chronic medical and mental status or having issues in results of the screening examination.
- Who has a history of an extreme sensitivity of drugs that contain Rosiglitazone or drugs that have similar effect as Rosiglitazone (Pioglitazone), or drugs that contain the ingredients of Metformin or biguanidine drugs
- Who has a serious heart failure or a congestive heart failure that must be drug-treated
- A patient with hepatopathy
- A patient with severe nephropathy
- Who has diabetic ketoacidosis or a diabetic coma, or type 1 diabetes, or has history of acute metabolic acidosis or ketoacidosis
- A patient with serious infectious disease or severe injuries before and after a surgery
- Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders
- A patient who has kidney disease or renal insufficient that are caused by cardiovascular collapse (shock) and acute myocardial infarction (a male with higher serum creatinine of 1.5mg / dL, or less creatinine clearance of 80 mL / min)
- A patient who is being tested to inject radiological iodine contrast agent into blood vessels (ex: intravenous urography, intravenous cholangiography, angiography, using contrast medium computer tomography, etc.)
- Who has severe systematic infection or severe trauma
- Who has nutritional status, starvation, debilitating condition, pituitary dysfunction, or adrenal insufficiency patients
- Who has respiratory dysfunction, gastrointestinal disease
- Who is unable to take high fat foods
- Who cannot limit intake of grapefruit or grapefruit containing foods in 7 days from the first dosing of clinical testing drug to collect pharmacokinetic blood samples
- Test subjects who is not willing or unable to comply with guidelines described in this protocol
- A person who is not determined unsuitable to participate in this test by the researchers
Sites / Locations
- Chonbuk National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
RT group
TR group
Arm Description
R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
Outcomes
Primary Outcome Measures
AUClast of Lobeglitazone
Cmax of Lobeglitazone
AUClast of Metformin
Cmax of Metformin
Secondary Outcome Measures
AUCinf of Lobeglitazone
Tmax of Lobeglitazone
t1/2 of Lobeglitazone
CL/F of Lobeglitazone
Vd/F of Lobeglitazone
AUCinf of Metformin
Tmax of Metformin
t1/2 of Lobeglitazone
CL/F of Metformin
Vd/F of Metformin
Full Information
NCT ID
NCT02685774
First Posted
February 15, 2016
Last Updated
August 8, 2017
Sponsor
Chong Kun Dang Pharmaceutical
1. Study Identification
Unique Protocol Identification Number
NCT02685774
Brief Title
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
Official Title
A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500 mg in Healthy Male Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
February 2016 (Actual)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
April 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is a randomized, open-label, single dose, 2-way crossover study to compare the pharmacokinetic characteristics of CKD-395 0.25/500 mg in healthy male volunteers.
Detailed Description
To healthy male subjects of twenty six(26), following treatments are administered dosing in each period fed condition(high fat meals) and wash-out period is a minimum of 7 days.
Treatment A(Reference Drug): DuvieTM Tab. 0.5mg 1T + Glucophage XR Tab. 500mg 2T Treatment B(Test Drug): CKD-395 0.25/750mg Tab. 2T
Pharmacokinetic blood samples are collected up to 48hrs. Safety and pharmacokinetic are assessed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type II
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
RT group
Arm Type
Other
Arm Description
R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T) T: Test drug(CKD-395 0.25/500mg 2T)
Arm Title
TR group
Arm Type
Other
Arm Description
T: Test drug(CKD-395 0.25/500mg 2T) R: Reference drug(Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T)
Intervention Type
Drug
Intervention Name(s)
Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
Other Intervention Name(s)
Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg
Intervention Description
Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
Intervention Type
Drug
Intervention Name(s)
CKD-395 0.25/500mg
Intervention Description
CKD-395 0.25/500mg 2T oral administration
Primary Outcome Measure Information:
Title
AUClast of Lobeglitazone
Time Frame
0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Title
Cmax of Lobeglitazone
Time Frame
0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Title
AUClast of Metformin
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 and 48hrs
Title
Cmax of Metformin
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 and 48hrs
Secondary Outcome Measure Information:
Title
AUCinf of Lobeglitazone
Time Frame
0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Title
Tmax of Lobeglitazone
Time Frame
0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Title
t1/2 of Lobeglitazone
Time Frame
0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Title
CL/F of Lobeglitazone
Time Frame
0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Title
Vd/F of Lobeglitazone
Time Frame
0(Pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 and 48hrs
Title
AUCinf of Metformin
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 and 48hrs
Title
Tmax of Metformin
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 and 48hrs
Title
t1/2 of Lobeglitazone
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 and 48hrs
Title
CL/F of Metformin
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 and 48hrs
Title
Vd/F of Metformin
Time Frame
0(Pre-dose), 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24 and 48hrs
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
A healthy male whose age is over 19 years old when visiting for initial screening test
Body mass index (BMI) between 17.5 ~ 30.5 kg/m^2 and the body weight must be over 55kg
Body mass index (BMI) = weight (kg) / height (m)^2
A male with no congenital or chronic disease in three years, no history of symptoms in internal treatment, or no knowledge in the area
Due to the special characteristics of drugs, the participators must be qualified to do the clinical screening after examined through hematology test and blood chemistry analysis, urinary test, the electrocardiogram (ECG), and etc.
The participants must be volunteered and sign in an informed consent document proven by Chonbuk National University IRB before joining a study to show that he was given informed the purpose of tests and the special characteristics of drugs.
The participants must have an ability and willingness to participate throughout the entire trials
Exclusion Criteria:
A person who had a history or symptoms of clinically aware of blood, kidney, internal secretion, gastrointestinal, urinary system, cardiovascular, liver, mental, nervous, or allergic (except subclinical seasonal allergies that is not treated at injection) disease.
Who had a history of gastrointestinal related disease which can be affected the drug absorption (esophageal achalasia, esophagostenosis, esophageal disease, or Crohn's disease) or surgeries (except a simple appendectomy or herniotomy)
Who had following results after examination
a. ALT or AST > twice higher than normal value
Who constantly intake 210 g/week of alcohol within 6 months of the screening. (a cup of beer (5%) (250mL) = 10 g, a shot of soju (20%) (50mL) = 8 g, a glass of wine (12%) (125 mL) = 12 g)
Who participated other clinical test or took testing bioequivalence drugs in 3 months before the first clinical drug trial
Whose blood pressure > 140 mmHg (systolic blood pressure) or > 90 mmHg (diastolic pressure)
Who had a medical history of alcohol and drug abuses.
Who had taken a drug that has a control of metabolic rate (activation or inhibition) in 30 days before the first taking of clinical testing drug
Who smokes more than 20 cigarettes per day
Who took prescribed drugs or over-the-counter drugs in 10 days before taking of very first clinical testing drug
Who participated in whole blood donation in 2 months before the first taking of clinical testing drugs or platelet donations in 1 month before the first taking to clinical testing drugs.
Who has a potent to increase a danger by participating in the clinical trials or who can interrupt interpreting test results by having serious or chronic medical and mental status or having issues in results of the screening examination.
Who has a history of an extreme sensitivity of drugs that contain Rosiglitazone or drugs that have similar effect as Rosiglitazone (Pioglitazone), or drugs that contain the ingredients of Metformin or biguanidine drugs
Who has a serious heart failure or a congestive heart failure that must be drug-treated
A patient with hepatopathy
A patient with severe nephropathy
Who has diabetic ketoacidosis or a diabetic coma, or type 1 diabetes, or has history of acute metabolic acidosis or ketoacidosis
A patient with serious infectious disease or severe injuries before and after a surgery
Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose malabsorption or genetic disorders
A patient who has kidney disease or renal insufficient that are caused by cardiovascular collapse (shock) and acute myocardial infarction (a male with higher serum creatinine of 1.5mg / dL, or less creatinine clearance of 80 mL / min)
A patient who is being tested to inject radiological iodine contrast agent into blood vessels (ex: intravenous urography, intravenous cholangiography, angiography, using contrast medium computer tomography, etc.)
Who has severe systematic infection or severe trauma
Who has nutritional status, starvation, debilitating condition, pituitary dysfunction, or adrenal insufficiency patients
Who has respiratory dysfunction, gastrointestinal disease
Who is unable to take high fat foods
Who cannot limit intake of grapefruit or grapefruit containing foods in 7 days from the first dosing of clinical testing drug to collect pharmacokinetic blood samples
Test subjects who is not willing or unable to comply with guidelines described in this protocol
A person who is not determined unsuitable to participate in this test by the researchers
Facility Information:
Facility Name
Chonbuk National University Hospital
City
Jeonju-si
State/Province
Jeollabuk-do
Country
Korea, Republic of
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers
We'll reach out to this number within 24 hrs